Notice of Intent to Publish a Funding Opportunity Announcement for Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01)

Notice Number: NOT-HL-17-493

Key Dates
Release Date: April 24, 2017

Estimated Publication Date of Announcement: September 2017
First Estimated Application Due Date: October 2020
Earliest Estimated Award Date: July 2021
Earliest Estimated Start Date: August 2021

Related Announcements

Issued by
National Heart, Lung, and Blood Institute (NHLBI)  


The National Heart, Lung and Blood Institute (NHLBI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) which will support hybrid effectiveness-implementation trials for heart, lung, blood, and sleep (HLBS) diseases in the inpatient setting. This FOA proposes to support trials testing an implementation strategy (or strategies) aimed at increasing implementation of an evidence-based practice(s).  

This Notice is being provided to allow potential applicants sufficient time to develop responsive projects. 

The FOA is expected to be published in September2017 with an anticipated application receipt date in October 2020.

This FOA will utilize the U01 activity code. Details of the planned FOA are provided below.

Research Initiative Details

The intended FOA will seek applications for hybrid effectiveness-implementation trials for HLBS diseases in the inpatient setting. The trial must examine both clinical and implementation outcomes, with a main focus on implementation outcomes. The implementation strategy (or strategies) being tested in the trial must have been developed utilizing an implementation research framework.

Trial designs should be as rigorous as possible, and randomized trial designs (e.g., cluster randomized, stepped wedge cluster randomized) are encouraged. Studies may be single or multi-site.

Application budgets are limited to $400,000 in direct costs in Year 1 and $675,000 in direct costs in Years 2-5. The maximum project period is 5 years. Foreign components are not allowed except for Canadian components.

Applicants will be required to have a multidisciplinary research team that includes expertise in inpatient clinical research, implementation research, and biostatistics. Applicants do not need to have been an awardee of the U34, described in NOT-HL-17-492, in order to apply.



Please direct all inquiries to:

Lora Reineck, MD, MS
Division of Lung Diseases
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0222

Catherine Stoney, PhD
Division of Cardiovascular Sciences
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-6670

Cheryl Boyce, PhD
Center for Translation Research and Implementation Science
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-496-1051

Andrei Kindzelski, MD, PhD
Division of Blood Diseases and Resources
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0050